Vasoplegia During Cardiac Surgery: Current Concepts and Management

Seminars in Thoracic and Cardiovascular Surgery

Volumn 22, Issue 2, 2010, Pages 140-144

  Fischer, Gregory W ^a   Levin, Mathew A ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Cardiac surgery; Cardiopulmonary bypass; Vasoplegia

Indexed keywords

HYPERTENSIVE FACTOR; METHYLENE BLUE; NORADRENALIN; PHENYLEPHRINE; PLACEBO; VASOPRESSIN;

ARTICLE; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; FLUID THERAPY; HEART ARRHYTHMIA; HEART OUTPUT; HEMOLYTIC ANEMIA; HUMAN; HYPOTENSION; INCIDENCE; INTESTINE ISCHEMIA; LOW DRUG DOSE; LUNG VASCULAR RESISTANCE; MESENTERY DISEASE; MESENTERY ISCHEMIA; PATHOPHYSIOLOGY; PEROPERATIVE CARE; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; PROGNOSIS; SHOCK; SIDE EFFECT; SKIN DISCOLORATION; SURGICAL MORTALITY; SYSTEMIC VASCULAR RESISTANCE; URINE; VASOPLEGIC SYNDROME;

CARDIAC SURGICAL PROCEDURES; CARDIOPULMONARY BYPASS; FLUID THERAPY; HEMODYNAMICS; HUMANS; RISK FACTORS; TREATMENT OUTCOME; VASOCONSTRICTOR AGENTS; VASOPLEGIA;

EID: 78449270337     PISSN: 10430679     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semtcvs.2010.09.007     Document Type: Article

References (25)

1. Cremer J., Martin M., Redl H., et al. Systemic inflammatory response syndrome after cardiac operations. Ann Thorac Surg 1996, 61:1714-1720.
2. Levin R.L., Degrange M.A., Bruno G.F., et al. Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery. Ann Thorac Surg 2004, 77:496-499.
3. Levin M.A., Lin H.M., Castillo J.G., et al. Early on-cardiopulmonary bypass hypotension and other factors associated with vasoplegic syndrome. Circulation 2009, 120:1664-1671.
4. Shanmugam G. Vasoplegic syndrome-the role of methylene blue. Eur J Cardiothorac Surg 2005, 28:705-710.
5. Surks H.K., Mochizuki N., Kasai Y., et al. Regulation of myosin phosphatase by a specific interaction with cGMP-dependent protein kinase. I. Science 1999, 286:1583-1587.
6. Mekontso-Dessap A., Houël R., Soustelle C., et al. Risk factors for post-cardiopulmonary bypass vasoplegia in patients with preserved left ventricular function. Ann Thorac Surg 2001, 71:1428-1432.
7. Carrel T., Englberger L., Mohacsi P., et al. Low systemic vascular resistance after cardiopulmonary bypass: Incidence, etiology, and clinical importance. J Cardiovasc Surg 2000, 15:347-353.
8. Gomes W.J., Erlichman M.R., Batista-Filho M.L., et al. Vasoplegic syndrome after open heart surgery. J Cardiovasc Surg (Torino) 1998, 39:619-623.
9. Argenziano M., Chen J.M., Choudhri A.F., et al. Management of vasodilatory shock after cardiac surgery: Identification of predisposing factors and use of a novel pressor agent. J Thorac Cardiovasc Surg 1998, 116:973-980.
10. Landry D.W., Oliver J.A. The pathogenesis of vasodilatory shock. N Engl J Med 2001, 345:588-595.
11. Morales D.L., Garrido M.J., Madigan J.D., et al. A double-blind randomized trial: Prophylactic vasopressin reduces hypotension after cardiopulmonary bypass. Ann Thorac Surg 2003, 75:926-930.
12. Klinzing S., Simon M., Reinhart K., et al. High-dose vasopressin is not superior to norepinephrine in septic shock. Crit Care Med 2003, 31:2646-2650.
13. Palmer R.M.J. The discovery of nitric oxide in the vessel wall. A unifying concept in the pathogenesis of sepsis. Arch Surg 1993, 128:396-401.
14. Mayer B., Brunner F., Schmidt K. Novel actions of methylene blue. Eur Heart J 1993, I(14 suppl):22-26.
15. Beasley D., McGuiggin M. Interleukin 1 activates soluble guanylate cyclase in human vascular smooth muscle cells through a novel nitric oxide-independent pathway. J Exp Med 1994, 179:71-80.
16. Schmidt H.H. NO, CO and OH. Endogenous soluble guanylyl cyclase-activating factors. FEBS Lett 1992, 307:102-107.
17. Myles P.S., Leong C.K., Currey J. Endogenous nitric oxide and low systemic vascular resistance after cardiopulmonary bypass. J Cardiothorac Vasc Anesth 1997, 11:571-574.
18. Leyh R.G., Kofidis T., Strüber M., et al. Methylene blue: The drug of choice for catecholamine-refractory vasoplegia after cardiopulmonary bypass?. J Thorac Cardiovasc Surg 2003, 125:1426-1431.
19. Kofidis T., Strüber M., Wilhelmi M., et al. Reversal of severe vasoplegia with single-dose methylene blue after heart transplantation. J Thorac Cardiovasc Surg 2001, 122:823-824.
20. Evora P.R. Should methylene blue be the drug of choice to treat vasoplegias caused by cardiopulmonary bypass and anaphylactic shock. J Thorac Cardiovasc Surg 2000, 119:632-634.
21. Grayling M., Deakin C.D. Methylene blue during cardiopulmonary bypass to treat refractory hypotension in septic endocarditis. J Thorac Cardiovasc Surg 2003, 125:426-427.
22. Sparicio D., Landoni G., Pappalardo F., et al. Methylene blue for lithium-induced refractory hypotension in off-pump coronary artery bypass graft: Report of two cases. J Thorac Cardiovasc Surg 2004, 127:592-593.
23. Ozal E., Kuralay E., Yildirim V., et al. Preoperative methylene blue administration in patients at high risk for vasoplegic syndrome during cardiac surgery. Ann Thorac Surg 2005, 79:1615-1619.
24. Maslow A.D., Stearns G., Butala P., et al. The hemodynamic effects of methylene blue when administered at the onset of cardiopulmonary bypass. Anesth Analg 2006, 103:2-8.
25. Scott D.M., Cooper M.G. Spurious pulse oximetry with intrauterine methylene blue injection. Anaesthesiol Intensive Care 1991, 19:267-268.